TABLE 2.
Clinical Characteristics and Outcome Analysis for miTrN0M0 Cohort*
| Characteristic | miTrN0M0 cohort (n = 127) | Completely covered by CTV (n = 68) | Partially covered by CTV (n = 43) | Not covered by CTV (n = 16) | P |
|---|---|---|---|---|---|
| No. of patients† | 127 (100) | 68 (54) | 43 (34) | 16 (13) | Not applicable |
| Median age (y)‡ | 70 (64–73) | 69.5 (62–72) | 70 (67–75) | 68.5 (66.3–75.3) | 0.14§ |
| Median serum PSA level (ng/mL)‡ | 1.02 (0.5–2.18) | 1.11 (0.5–2.2) | 1.09 (0.46–2.63) | 0.84 (0.62–1.11) | 0.26§ |
| Median tumor volume (mL)‡ | 0.72 (0.38–1.35) | 0.57 (0.36–1.13) | 1.01 (0.49–67) | 0.68 (0.37–0.96) | 0.12§ |
| NCCN risk group∥ | 0.38¶ | ||||
| Low risk | 8 (8) | 7 (10) | 0 (0) | 1 (6) | |
| Intermediate risk | 54 (51) | 26 (38) | 19 (44) | 8 (50) | |
| High risk | 28 (26) | 12 (18) | 12 (28) | 4 (25) | |
| Very high risk | 16 (15) | 9 (13) | 5 (12) | 2 (13) | |
| Not available | 21 | 14 | 7 | 1 | |
| Surgical margin involvement∥ | 0.04# | ||||
| No | 58 (65) | 21 (45) | 20 (69) | 12 (92) | |
| Yes | 31 (35) | 26 (55) | 9 (31) | 1 (8) | |
| Not available | 38 | 21 | 16 | 4 | |
| Location of recurrence partially or completely exceeding CTV∥ | Not applicable | Not applicable | |||
| Total no. | 59 (100) | 43 (100) | 16 (100) | ||
| Posterior | 30 (52) | 25 (58) | 5 (31) | ||
| Posterolateral | 14 (24) | 10 (23) | 4 (25) | ||
| Posteroinferior | 3 (5) | 1 | 2 (13) | ||
| Anterior | 1 (2) | 1 (2) | 0 | ||
| Superior | 1 (2) | 1 (2) | 0 | ||
| Inferior | 10 (14) | 5 (10) | 5 (31) | ||
| Local extension∥ | 0.002# | ||||
| Rectal wall involvement | 12 (9) | 1 (1) | 5 (12) | 6 (38) | |
| Bladder wall involvement | 4 (3) | 4 (6) | 0 | 0 |
*
Age and PSA level are at time of PET. Percentages were calculated on basis of total number of patients with data available in selected category.
†
Values in parentheses are percentages of total number of patients.
‡
Values in parentheses are interquartile ranges.
§
One-way ANOVA.
∥
Reported as number of patients, with percentages in parentheses. NCCN = National Comprehensive Cancer Network.
¶
Spearman (ρ) correlation matrix.
#
χ2 test.